Therefore, a large number of clinical trials have both been conducted and are currently underway to determine whether targeting CB1R directly or affecting the degradation rate of eCBs through FAAH and MAGL inhibitors can be used in a wide variety of disorders ranging from anxiety to epilepsy (van Egmond et al., 2021); however, there is still a lack of clinical data to determine whether these compounds will be efficacious across the general population. This evidence concerns the gene MGLL and epilepsy.